Scope Fluidics Sa · GPW:SCP
Scope Fluidics Sa — Investor Day (January 2025)
36 slides from Scope Fluidics Sa's investor day presentation, January 2025
Slide 1: Scope Fluidics Investors Day
SCOPE FLUIDICS Investors Day January 2025
Slide 2: Disclaimers
DISCLAIMERS Niniejsza prezentacja (“Prezentacja”) zawiera podstawowe informacje dotyczące Scope Fluidics S.A. („Spółka”) oraz grupy kapitałowej Scope Fluidics S.A. („Grupa”). Prezentacja została przygotowana wyłącznie w celu przedstawienia podstawowych informacji o Grupie i jej działalności. Prezent
Slide 3: Unique combination of competencies in technology, operations and financial areas
UNIQUE COMBINATION OF COMPETENCIES IN TECHNOLOGY, OPERATIONS AND FINANCIAL AREAS MANAGEMENT BOARD OF SCOPE FLUIDICS MARCIN IZYDORZAK PROF. PIOTR GARSTECKI SZYMON RUTA VICE PRESIDENT CEO VICE PRESIDENT, CFO Co-founder of Scope Fluidics Co-founder of Scope Fluidics Responsible for financial division,
Slide 4: Agenda for today
SCOPE FLUIDICS Agenda for today 1. Scope Fluidics 2. BACTEROMIC 3. Tours and side presentations ✓ BACTEROMIC – walk-through ✓ BACTEROMIC – labs & manufacturing short presentation ✓ BACTEROMIC – presentation of the system ✓ Scope Discovery and PMR – short presentetions 4. Edocera 5. Hybolic 4
Slide 5: Venture Studio - our values and vision for success
SCOPE FLUIDICS Venture Studio - our values and vision for success We address global challenges in healthcare and develop technologies with PEOPLE COURAGE clear, significant impact. We aim at +USD 109 markets NETWORK PROCESSES and develop technologies that can readily be leveraged by large, multinati
Slide 6: Corporate structure supports execution of M&A transactions
VENTURE STUDIO BUSINESS MODEL Corporate structure supports execution of M&A transactions Each project in Scope Fluidics’ Group is developed in a separate, legal entity (SPV) 100% ownership of the SPVs Sold to Bio-Rad Laboratories Each subsidiary is focused on August 2022 the R&D activities and has t
Slide 7: 140 employees, 20+ PhDs, 3 SPVs, Scope Discovery
Know-how and capacity to bring products from identification of challenge to market access. 140 employes, 20+ PhDs, 3 SPVs, Scope Discovery After 15 years on the market we have all specialities on board for development of technologies from zero to launch of products on the market, together with an ex
Slide 8: 15 Years of Systematic Growth
15 Years of Systematic Growth: Building an Even Stronger Future From a 10k PLN start-up to a largest med-tech venture studio in CEE 2010 Founded for PLN 10k 2010-2015 Two generations of BlueBox, EUR 6m turnover 2012 Launch of Curiosity Diagnostics 2017 Founding of the Bacteromic company 2017 New Con
Slide 9: Financial track record – outstanding return on investment and dynamic outlook
SCOPE FLUIDICS Financial track record – outstanding return on investment and dynamic outlook for future developments. USD 130m revenue from sales of PCR I One USD 100m market cap (10x since IPO) USD 50m dividend payed out in 2023 BACTEROMIC developed to the pre IVDR stage Raised Stable cash position
Slide 10: Projects Pipeline
SCOPE DISCOVERY Projects Pipeline 29 projects assessed: • 15 projects closed • 12 ongoing projects • 2 SPVs launched 11 24 10 7 12 18 18 18 5 8 22 3 3 9 17 26 1 EDOCERA 14 1 HYBOLIC CONCEPT PROOF-OF-CONCEPT SPV STRATEGIC TRANSACTION Number of dots does not represent actual numer of projects 10
Slide 11: Key value-building stages
SCOPE FLUIDICS Key value-building stages Launching product on the market increases its attractiveness and value $$ $$$$ Technology Team of professionals Market traction Laboratory Market feedback (Early Access) Patent protection First clients Clinical performance Revenue Certification Profitability
Slide 12: Scope Fluidics Strategy
SCOPE FLUIDICS Scope Fluidics Strategy By the end of 2025 having at least five new projects in the portfolio, 1 including at least two STRATEGIC TRANSACTIONS: in the form of special purpose vehicles 1. Sale of all shares in special purpose vehicles developing By the end of 2028 breakthrough technolo
Slide 13: Agenda for today
SCOPE FLUIDICS Agenda for today 1. Scope Fluidics 2. BACTEROMIC 3. Tours and side presentations ✓ BACTEROMIC – walk-through ✓ BACTEROMIC – labs & manufacturing short presentation ✓ BACTEROMIC – presentation of the system ✓ Scope Discovery and PMR – short presentetions 4. Edocera 5. Hybolic 13
Slide 14: Fastest access to precision antibiotic therapies
Leading the Next Generation of AST solutions Fastest access to precision antibiotic therapies High-content, automated antibiotic susceptibility testing with rapid, same-shift results Rapid | Versatile | Super Informative | Cost-effective For private use only 14
Slide 15: The best system for the evolving Antibiotic Susceptibility Testing market
The best system for the evolving Antibiotic Susceptibility Testing market For private use only. Not for publication or distribution. 15
Slide 16: Antibiotic resistance – one of biggest threats to human health
Antibiotic resistance – one of biggest threats to human health September 26th, 2024 Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), committing to a clear set of targets and actions, includin
Slide 17: Antibiotic resistance – one of biggest threats to human health
Antibiotic resistance – one of biggest threats to human health September 26th, 2024 Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), committing to a clear set of targets and actions, includin
Slide 18: What is Antibiotic Susceptibility Test (AST)?
What is Antibiotic Susceptibility Test (AST)? AST Report vs Patient: John Kowalski Bacteria: Escherichia coli Bacteria Antibiotic Susceptibility Antibiotics MIC Category Amoxicillin 4 μg/ml S 1 Cephazolin 0,25 μg/ml S Minimum inhibitory Ceftazidime 16 μg/ml R concentration (MIC) The smallest concent
Slide 19: Customer options
Market analysis Customer options MANUAL AUTOMATED Disk diffusion E-tests Broth microdilution Automated Automated • The cheapest • Cheap • Golden standard (standard) (specialized) • Well known • MIC • MIC • High-throughput • New applications • Automated • Rapid • Laborious • Laborious • Laborious • L
Slide 20: User-centric design and compliance
User Advantages User-centric design and compliance Analyzer Analyzer: • Capacity for 60 Cartridges – high throughput with Filling random access Disposable Device • <6h Time to Result Cartridge • LIS connectivity Filling Device: • Quick, fully automated procedure of inoculation & sealing for up to 10
Slide 21: For private use only. Not for publication or distribution.
For private use only. Not for publication or distribution. 22
Slide 22: Unmatched Data Density with 640 Incubation Chambers
Information content Unmatched Data Density with 640 Incubation Chambers The widest antibiotics menu – up to 60 antibiotics with real MICs in a single assay 64 wells 384 wells BACTEROMIC offers 640 incubation chambers, the highest in the industry, enabling rapid AST 96 wells across all antibiotics in
Slide 23: 640 Incubation Chambers: the highest information content
The highest information content The most comprehensive & precise AST information 640 INCUBATION CHAMBERS TO PROVIDE THE MOST COMPREHENSIVE AST PANEL: up to 60 antibiotics UNPRECEDENTED INFORMATION CONTENT up to 14 dilutions GOLDEN STANDARD True MIC TWO-FOLD DILUTION SERIES in a single Panel per anti
Slide 24: Addressing critical global healthcare challenge
Market analysis Addressing critical global healthcare challenge Opportunity to serve a growing and evolving market demand 5,7 Culture isolates CAGR Global AST diagnostics market (USD bn) 4,0 5.5% • "AMR could cause 10 million deaths annually by 2050" (Jim O’Neill Report) • "Currently, AMR is linked
Slide 25: Competition: status quo with separate systems
Competition Status quo – separate systems with complex product portfolios AST 1 AST 2 Isolates AST AST 3 ? AST 4 days of delay Slow, complex product Ordering Risk of repeated portfolio, only for Portfolios of 10-15+ multiple panel testing panels with Stocking Risk of error in isolates limited antibi
Slide 26: AST market requirements
Market analysis AST market requirements Culture isolates Single dilution All relevant • High antibiotics in 30-150 5-30 € sample one test tests/day per panel throughput preparation (ease of use) (broad drug (high volumes) (low margin) • Low price coverage) Blood culture All relevant Single dilution
Slide 27: AST market needs future-proof, informative, rapid system
AST market needs future-proof, informative, rapid system that offers synergies across isolate and PBC market segments For private use only. Not for publication or distribution. 28
Slide 28: Automatic AST market
Market analysis Automatic AST market Standard AST (16-24 h) Rapid AST (2-8 h) Culture isolates Vitek (in development) Blood culture No market 29
Slide 29: Simplifying and maximizing AST value chain
Common platform for two markets Simplifying and maximizing AST value chain Same Cartridge architecture & analyzers for both PBC and Isolates. Information capacity minimizes number of distinct panels. Isolates AST Less storage Compatible with Fastest access to same Cartridge precision space, Bacterom
Slide 30: Updated goals for BACTEROMIC
BACTEROMIC Updated goals for BACTEROMIC ESPI 05/2024 – may 2024 Commercial introduction of BACTEROMIC system to the international market: a) Obtaining contracts for purchase of the BACTEROMIC system b) IVDR certification of the BACTEROMIC system’s components c) Securing external manufacturing capaci
Slide 31: FAST detection – preliminary R&D results
FAST detection – preliminary R&D results • Bacteromic is ready for rapid AST of clinically applicable antibiotic-bacteria combinations under IVDR standards Goal: • To be implemented for PBC, as well as Isolates same-shift • Results of Panel FAST after analytical performance evaluation on AST results
Slide 32: IVDR certification of the BACTEROMIC system's components
BACTEROMIC IVDR certification of the BACTEROMIC system’s components Agreement with Start of IVDR Notified Body (Panel Clinical Performence certification UNI and Interpreter) Evaluation Signed in Started in Planned in September 2024 November 2024 H2’2025 33
Slide 33: Securing external manufacturing capacity
MANUFACTURING Securing external manufacturing capacity ANALYZER & FILLING DEVICE OEM CARTRIDGE PRODUCTION LINE: several hundred k/year November 2024 - cooperation with TE Connectivity for design and setup of semi-automated line in Spain November 2023 - launched cooperation with BIT Launch planned by
Slide 34: Intellectual Property – patent portfolio
IP & Patents Intellectual Property – patent portfolio Recent updates: January 2024 – US patent granted for METHOD AND SYSTEM MICROFLUIDIC CHIP „Microfluidic Chip” The invention is intended for FOR RAPIDLY TESTING microbiological testing cards, ANTIMICROBIAL SUSCEPTIBILITY particularly for microbial
Slide 35: Patent Portfolio
Intellectual Property Patent Portfolio MICROFLUIDIC CHIP METHOD AND SYSTEM FOR RAPIDLY TESTING ANTIMICROBIAL SUSCEPTIBILITY INCUBATION SEGMENT WITH AN UNVENTED GAS CAVITY METHOD AND SYSTEM IN A MICROFLUIDIC CHIP FOR PREDICTION OF MICROORGANISM GROWTH USING ARTIFICIAL INTELLIGENCE A SYRINGE-PLUG AND
Slide 36: M&A activity in 2024
BACTEROMIC M&A activity in 2024 JP Morgan January Healthcare Conference San Francisco ECCMID April Barcelona EIB Alumn Event May Luxembourg JP Morgan June Healthcare Symposium London ADLM July Chicago MEDICA November Dusseldorf Jefferies November Healthcare Conference London